英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
undoubtful查看　undoubtful　在百度字典中的解释百度英翻中〔查看〕
undoubtful查看　undoubtful　在Google字典中的解释Google英翻中〔查看〕
undoubtful查看　undoubtful　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
    Rizvi NA, Hellmann MD, Brahmer JR, et al Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer J Clin Oncol 2016;34:
  • Nivolumab in the treatment of metastatic squamous non-small cell lung . . .
    Progress in the treatment of patients with advanced stage squamous cell non-small cell lung cancer (NSCLC) has been limited An improvement in the understanding of tumor immunosurveillance has resulted in the development of the immune checkpoint inhibitors such as nivolumab
  • Nivolumab Approved for Neoadjuvant and Adjuvant Treatment of Non-small . . .
    The immunotherapy is now approved to treat certain lung cancers before and after surgery The U S Food and Drug Administration (FDA) has approved neoadjuvant nivolumab (Opdivo) with platinum-containing chemotherapy, followed by adjuvant nivolumab alone, for patients with non-small cell lung cancer (NSCLC) that can be surgically removed, is 4 cm or larger or has spread to the lymph nodes, and
  • Non-Small Cell Lung Cancer (NSCLC) Treatment | OPDIVO® (nivolumab)
    OPDIVO® (nivolumab) alone, or with YERVOY® (ipilimumab) can be used as an immunotherapy treatment option for adults with certain types of NSCLC Please see Indication and Important Safety Information Select your cancer type Non-small cell lung cancer (NSCLC) Advanced kidney cancer; Gastroesophageal cancer; Melanoma;
  • Nivolumab and Chemotherapy for Early-Stage Lung Cancer
    Non-small cell lung cancer, the most common form of lung cancer, has often already spread beyond the lungs when it is diagnosed, so research has largely focused on people with more advanced forms of the disease After a follow-up of at least 21 months, the patients who received nivolumab treatment lived on average 11 months longer without
  • Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer - Medscape
    Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3
  • Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall . . .
    Among adults with stage 1B to 3A resectable non-small cell lung cancer (R-NSCLC), nivolumab (Opdivo; Bristol Myers Squibb) in combination with chemotherapy—followed by surgery—demonstrated a statistically significant overall survival (OS) benefit compared with chemotherapy alone while continuing to improve event-free survival (EFS)
  • US Food and Drug Administration Approval Summary: Nivolumab Plus . . .
    Approximately 84% of patients with newly diagnosed lung cancer have non–small-cell lung cancer (NSCLC), 1 of whom 25%-30% may have resectable disease at diagnosis 2 Surgical resection is the primary treatment modality for patients with early-stage NSCLC who are deemed fit for surgery, 3 and this may be followed by adjuvant systemic therapy An alternative approach to adjuvant systemic
  • Nivolumab plus ipilimumab versus carboplatin-based doublet as first . . .
    Lung cancer is the leading cause of cancer-related deaths in high-income countries and 85% of lung cancer cases are non-small-cell lung cancer (NSCLC), which is diagnosed at the metastatic stage in the majority of patients 1 Compared with chemotherapy, first-line immunotherapy-based regimens for the treatment of advanced NSCLC have
  • Treatment-Free Survival Over 6 Years of Follow-up in Patients With . . .
    Nivolumab plus ipilimumab improved TFS versus chemotherapy, regardless of tumor PD-L1 expression, supporting its use as an efficacious first-line treatment for metastatic NSCLC Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus





中文字典-英文字典  2005-2009